Thus, to address this immunogenicity question, specifically, the induction of ADAs, we used a mouse model of acute DSS colitis in which mice were orally administered with 30 μg of CTB-KDEL twice prior to 3% DSS exposure to induce an immunogenic response to the protein (the aforementioned vaccine dosing regimen [22]). This evidence concerns the gene AGPS and colitis.